- Home
- IPHA vs SKYX Comparison
IPHA vs SKYX Comparison
Compare IPHA & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- SKYX
- Stock Information
- Founded
- IPHA 1999
- SKYX 2004
- Country
- IPHA France
- SKYX United States
- Employees
- IPHA N/A
- SKYX N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- SKYX Building Products
- Sector
- IPHA Health Care
- SKYX Consumer Discretionary
- Exchange
- IPHA Nasdaq
- SKYX Nasdaq
- Market Cap
- IPHA 148.3M
- SKYX 129.2M
- IPO Year
- IPHA 2019
- SKYX 2022
- Fundamental
- Price
- IPHA $1.77
- SKYX $1.57
- Analyst Decision
- IPHA Strong Buy
- SKYX Strong Buy
- Analyst Count
- IPHA 1
- SKYX 3
- Target Price
- IPHA $11.50
- SKYX $4.00
- AVG Volume (30 Days)
- IPHA 42.3K
- SKYX 524.3K
- Earning Date
- IPHA 09-12-2024
- SKYX 11-12-2024
- Dividend Yield
- IPHA N/A
- SKYX N/A
- EPS Growth
- IPHA N/A
- SKYX N/A
- EPS
- IPHA N/A
- SKYX N/A
- Revenue
- IPHA $36,202,722.00
- SKYX $84,766,991.00
- Revenue This Year
- IPHA N/A
- SKYX $55.57
- Revenue Next Year
- IPHA $101.65
- SKYX $38.56
- P/E Ratio
- IPHA N/A
- SKYX N/A
- Revenue Growth
- IPHA N/A
- SKYX 131.47
- 52 Week Low
- IPHA $1.29
- SKYX $0.72
- 52 Week High
- IPHA $3.51
- SKYX $1.69
- Technical
- Relative Strength Index (RSI)
- IPHA 46.55
- SKYX 68.29
- Support Level
- IPHA $1.65
- SKYX $1.22
- Resistance Level
- IPHA $1.87
- SKYX $1.55
- Average True Range (ATR)
- IPHA 0.12
- SKYX 0.14
- MACD
- IPHA -0.03
- SKYX 0.02
- Stochastic Oscillator
- IPHA 33.47
- SKYX 96.75
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About SKYX SKYX Platforms Corp.
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. The company's technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post and is capable of feeding electric power to an appliance. The Company generates its income from the United States.